Effectiveness and safety profile of mepolizumab in chronic rhinosinusitis with nasal polyps: Real life data in a tertiary care.

Autor: Galletti C; Department of Adult and Developmental Human Pathology 'Gaetano Barresi', University of Messina, Messina, Italy. Electronic address: cosimogalletti92@gmail.com., Ciodaro F; Department of Adult and Developmental Human Pathology 'Gaetano Barresi', University of Messina, Messina, Italy., Barbieri MA; Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy., Gambino F; Department of Adult and Developmental Human Pathology 'Gaetano Barresi', University of Messina, Messina, Italy., Ferrisi MG; Department of Adult and Developmental Human Pathology 'Gaetano Barresi', University of Messina, Messina, Italy., Portelli D; Department of Adult and Developmental Human Pathology 'Gaetano Barresi', University of Messina, Messina, Italy., Catalano N; Department of Adult and Developmental Human Pathology 'Gaetano Barresi', University of Messina, Messina, Italy., Spina E; Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy., Freni F; Department of Adult and Developmental Human Pathology 'Gaetano Barresi', University of Messina, Messina, Italy., Galletti B; Department of Adult and Developmental Human Pathology 'Gaetano Barresi', University of Messina, Messina, Italy.
Jazyk: angličtina
Zdroj: American journal of otolaryngology [Am J Otolaryngol] 2024 Jul-Aug; Vol. 45 (4), pp. 104329. Date of Electronic Publication: 2024 Apr 21.
DOI: 10.1016/j.amjoto.2024.104329
Abstrakt: Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) is characterized by a type 2 pattern of inflammation. Mepolizumab was approved for the treatment of CRSwNP in 2021, it may be useful to evaluate its safety profile in a real-world setting.
Aim: This work aimed to prospectively highlight the effectiveness and safety profile of Mepolizumab in patients with CRSwNP enrolled in the Otorhinolaryngology Unit of the University Hospital of Messina.
Methods: An observational cohort study was carried out considering all patients treated with Mepolizumab. A descriptive analysis was conducted reporting all demographic characteristics, endoscopic evaluations, and symptom conditions.
Results: A total of 30 patients were treated with Mepolizumab, one patient discontinued the treatment. A statistically significant reduction in the Sino-Nasal Outcome Tests-22 (SNOT-22) and nasal polyp score (NPS) was shown at the 6th and 12th months compared to baseline values (SNOT-22, -33 and - 43, p < 0.001 for both comparisons; NPS, 0 and - 1, p < 0.001 for both comparisons). The median (Q1-Q3) sniffin' sticks test score increased from 7 (6-8) at the 6th month to 11 (10-13) at the 12th month. Seven patients (24.1 %) reported pain at the injection site, accompanied by redness, warmth, and tenderness within the first 24 h post-injection with a median duration of three days from the onset.
Conclusions: Given the optimal treatment response and the minimal adverse effects observed, clinicians should consider Mepolizumab a safe and effective treatment in CRSwNP patients. Further studies in real-life setting are necessary to better understand the long-term effects.
Competing Interests: Declaration of competing interest The authors declare no conflict of interest.
(Copyright © 2024 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: